People living with pre-existing heart disease who received a shingles vaccine experienced nearly half the rate of serious heart-related events within a year compared with those who were not vaccinated, according to compelling new research. These significant findings, poised to reshape discussions around preventive health strategies, are being presented at the American College of Cardiology’s Annual Scientific Session (ACC.26), underscoring a growing understanding of the systemic benefits of vaccination beyond their primary targets. The study provides robust evidence that the protective effects of the herpes zoster vaccine extend well into cardiovascular health, particularly for a highly vulnerable patient population already battling significant cardiac risk. Pivotal Findings for a High-Risk Population The extensive study meticulously reviewed data from more than 246,822 adults across the United States previously diagnosed with atherosclerotic heart disease (ASCVD). This condition, characterized by the insidious buildup of plaque within the arteries, affects millions globally and is the leading cause of heart attacks, strokes, and peripheral artery disease. The research highlights a profound reduction in major adverse cardiovascular events (MACE) among vaccinated individuals, signaling a potential paradigm shift in the management of patients with established heart conditions. Specifically, vaccinated individuals were found to be 46% less likely to experience a MACE within one year of vaccination. This overarching benefit was further broken down into substantial reductions across several critical cardiovascular outcomes: a 32% decrease in heart attack risk, a 25% reduction in stroke incidence, and a 25% lower likelihood of developing heart failure. Beyond these specific cardiac benefits, the study also revealed a striking 66% lower all-cause mortality rate in the vaccinated group, underscoring the vaccine’s broad protective impact. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke, and death," stated Robert Nguyen, MD, a resident physician at the University of California, Riverside, and the lead author of the groundbreaking study. Dr. Nguyen emphasized the particular significance of these findings for the study’s cohort: "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." This observation is critical because patients with ASCVD face a significantly elevated baseline risk for future cardiovascular events, making any intervention that substantially lowers this risk exceptionally valuable. The Mechanism Behind Cardioprotection: Unraveling the Shingles-Heart Link The Centers for Disease Control and Prevention (CDC) universally recommends the shingles vaccine for adults aged 50 years and older, as well as for younger individuals with compromised immune systems. The vaccine’s primary role is to protect against herpes zoster, the medical term for shingles. This painful viral infection manifests as a blistering rash, often accompanied by severe, long-lasting nerve pain known as postherpetic neuralgia (PHN), which can debilitate sufferers for months or even years. Shingles itself is a reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox, often occurring decades after the initial childhood infection when the immune system weakens due with age, stress, or illness. The connection between shingles and cardiovascular health, while seemingly disparate, is increasingly understood through the lens of systemic inflammation and its impact on the vascular system. Earlier research has demonstrated that an active shingles infection can trigger a cascade of inflammatory responses throughout the body. This inflammation can lead to endothelial dysfunction, where the inner lining of blood vessels becomes impaired, promoting the formation of blood clots. These clots, particularly when they form near vital organs like the brain and heart, can significantly increase the risk of ischemic events such as heart attacks and strokes. Furthermore, shingles infections have been implicated in promoting venous thromboembolism (VTE), another dangerous clotting condition. By effectively preventing the onset of shingles, the vaccine appears to interrupt this inflammatory cascade, thereby mitigating the associated cardiovascular risks. This suggests that the vaccine is not merely preventing a painful rash but actively safeguarding the body’s vascular integrity against a potent inflammatory trigger. Methodology and Robust Data Analysis To conduct this large-scale retrospective cohort study, researchers leveraged TriNetX, a comprehensive federated research network database that aggregates de-identified electronic medical records from millions of Americans across numerous healthcare organizations. The study specifically examined adults aged 50 years or older with a confirmed diagnosis of atherosclerotic disease between the years 2018 and 2025. The analysis involved two meticulously matched groups: 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine, and an equal number of individuals who had not been vaccinated against shingles. Critical to the study’s validity, both groups were carefully balanced based on a wide array of demographic factors (such as age, sex, race, and ethnicity) and pre-existing health conditions (comorbidities), ensuring that observed differences in outcomes could be more confidently attributed to vaccination status rather than confounding variables. Researchers then focused on heart-related outcomes that occurred between one month and one year following vaccination (or within an equivalent timeframe for the unvaccinated control group). This timeframe was chosen to allow sufficient time for the vaccine to confer immunity while also capturing acute and subacute cardiovascular events potentially averted by vaccination. The consistent and substantial risk reductions observed across all cardiovascular measures – including MACE, heart attack, stroke, heart failure, and all-cause mortality – provide compelling statistical evidence. Dr. Nguyen highlighted the magnitude of these reductions, noting they are "substantial and comparable to the benefits seen from quitting smoking." This powerful comparison underscores the potential public health impact of widespread shingles vaccination, particularly in at-risk populations. The Evolving Landscape of Shingles Vaccination The shingles vaccine landscape has seen significant advancements. For many years, Zostavax, a live-attenuated vaccine, was the only option. However, since 2017, Shingrix, a recombinant subunit vaccine, has become the preferred and more effective choice. Shingrix boasts over 90% efficacy in preventing shingles and postherpetic neuralgia across all age groups 50 and older, with protection remaining high for at least seven years. This superior efficacy, coupled with its non-live formulation (making it safe for immunocompromised individuals who cannot receive live vaccines), has led the CDC to recommend Shingrix over Zostavax. The widespread adoption of Shingrix has likely contributed to the robust findings of recent studies, as its higher efficacy against shingles infection would naturally translate to a greater reduction in shingles-related complications, including cardiovascular events. The economic burden of shingles is not insignificant. Beyond the direct medical costs associated with treating the rash and managing PHN, there are substantial indirect costs related to lost productivity and diminished quality of life. By preventing shingles, the vaccine offers both direct health benefits and potential economic savings. The added benefit of cardiovascular protection further strengthens the argument for universal adherence to vaccination guidelines. Broader Context: A Growing Body of Evidence This latest research from ACC.26 is not an isolated finding but rather reinforces a growing body of scientific literature suggesting a broader cardioprotective role for the shingles vaccine. In recent years, scientists have increasingly recognized the intricate links between viral infections, inflammation, and cardiovascular disease. For instance, studies have explored the association between influenza vaccination and reduced cardiovascular events in at-risk patients, highlighting a common theme: preventing infectious diseases can have positive ripple effects on systemic health, particularly the cardiovascular system. A prior study, published in 2025 (though the original article’s reference to a 2025 publication might be a typo for an earlier year, or predictive for an upcoming one), found that shingles vaccination was linked to a 23% reduction in cardiovascular events in generally healthy adults, with benefits that could last up to eight years. This earlier work laid crucial groundwork, demonstrating that the cardioprotective effect was not limited to those with existing heart conditions but extended to the broader adult population. The current study significantly builds upon this by focusing on the highest-risk group, where the absolute risk reduction translates into a more profound clinical impact. The consistency across these studies strengthens the scientific consensus around the vaccine’s dual benefits. Implications for Clinical Practice and Public Health The findings presented at ACC.26 carry substantial implications for clinical practice and public health messaging. For healthcare providers, these results offer another compelling reason to proactively recommend shingles vaccination, especially for their patients with atherosclerotic heart disease. It transforms the conversation from merely preventing a painful rash to actively protecting against life-threatening cardiac events. Dr. Nguyen emphasized this point: "Vaccines are one of the most important medicines we have to prevent disease. Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." In an era where vaccine hesitancy remains a significant public health challenge, providing clear, evidence-based benefits beyond the primary target disease can be a powerful tool in encouraging uptake. Public health campaigns could leverage this new information to enhance vaccine acceptance rates, potentially leading to a healthier aging population with a reduced burden of both shingles and cardiovascular disease. From a policy perspective, these data could inform discussions around vaccine accessibility and coverage. Recognizing the extensive benefits, particularly for high-risk individuals, might prompt healthcare systems and insurers to ensure broad access to the shingles vaccine. Limitations and Future Directions While robust, the study acknowledges certain limitations. The analysis primarily tracked outcomes during the first year after vaccination, meaning the long-term effects beyond this period warrant further investigation. Although previous research suggests benefits lasting up to eight years, specific long-term data for patients with existing ASCVD would provide even greater clarity. Furthermore, as with any observational study, the possibility of residual confounding exists. While researchers meticulously adjusted for numerous health and socioeconomic factors (including problems related to housing and economic circumstances, social environment, employment status, education, and literacy), it is plausible that individuals who choose to get vaccinated may also engage in a broader range of healthier behaviors not fully captured by the available data. This "healthy user bias" is a common consideration in observational research. However, the study’s immense sample size and rigorous statistical approach significantly bolster the evidence, indicating that the association between shingles vaccination and reduced heart risk is meaningful and robust. Future research will likely delve deeper into the precise molecular and cellular mechanisms by which the shingles vaccine confers cardiovascular protection. Understanding these pathways could lead to new therapeutic targets for cardiovascular disease. Additionally, studies exploring the cost-effectiveness of widespread shingles vaccination, considering its multi-faceted benefits, would provide valuable data for healthcare policy decisions. Dr. Nguyen is scheduled to present the study, "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," on Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E, at the ACC.26 conference. The presentation is expected to generate significant discussion among cardiologists, infectious disease specialists, and public health experts, solidifying the shingles vaccine’s critical role in comprehensive preventive healthcare. Post navigation A Decade of Northwestern Research Reveals Physical Arrangement of Vaccine Ingredients Dramatically Influences Performance Against Cancer
